Renewed hope for gene therapy
This article was originally published in Scrip
Executive Summary
Hard on the heels of the news that a Russian biotech firm has become the first company to get a gene therapy product approved for commercial use in Europe (scripintelligence.com, 7 December) comes the publication of a study that shows for the first time that a gene therapy product is capable of eliciting a sustained therapeutic response even after a single dose.